JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v2i3.2145 jpsim.v2i3.2145 Review Article Why Ivermectin, Azithromycin, Meplazumab and Vitamin D Helps to Control the Severity of SARS-CoV-2. The Role of ACE-2 and CD147 During Coronavirus Infection Bukhari Mulazim Hussain mulazim.hussain@gmail.com * Rizwan Wajiha Azad Jammu Kashmir Medical College, Muzaffarabad *Correspondence: Mulazim Hussain Bukhari (mulazim.hussain@gmail.com) 20 09 2021 2021 2 3 190 194 02 05 2021 31 07 2021 Copyright © 2021 The Author(s) 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As the world faces pandemic of COVID-19, the search for effective treatments modalities against the disease and its

complications has turned its gaze to drugs that are classically used in other infectious diseases.

Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation. The aim of the study was to review the mechanism of action of Ivermectin, Azithromycin, Hydroxycholoquine, and vitamin D therapy being used in the literature. This review found that the drugs might mitigate disease progression without significant adverse effects and can be used prophylactically, during the disease and after recover when in long hauler state. Further cohort studies are needed in order to extrapolate these findings in COVID-19. The discovery of CD147 will open the channel to discover some new more potent target therapeutic drugs.

 Keywords Coronavirus COVID-19 Ivermectin. ACE2 CD147 Lucine Histidine SARS-CoV-2 References Weir EK, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19?. Clin Med (Lond). 2020;20(4):e107-e108. Cooling L. Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev. 2015 Jul;28(3):801-70. Wenzhong L, Hualan L. COVID-19 Disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv 2020; Preprint. 10.26434/chemrxiv.11938173.v3 Wenzhong L, Hualan L. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv 2020. Preprint. 10.26434/chemrxiv.11938173.v8. Rahim F, Amin S, Bahadur S, Noor M, Mahmood A, Gul H. ABO / Rh-D Blood types and susceptibility to Corona Virus Disease-19 in Peshawar, Pakistan. Pak J Med Sci. 2021;37(1):4-8. More Evidence Points to Role of Blood Type in COVID-19. [Updated 2021; cited 2021] Available from website: [https://www.medpagetoday.com/infectiousdisease/covid19/89117] Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo Sep. 2020, 34 (5) 3023-26. Zhang X, Song Y, Xiong H, Ci X, Li H, Yu L, Zhang L, Deng X. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol. 2009;9(3):354-9. Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, Song Y, Deng X. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23(4):449-55. Bangladesh Medical College Hospital Physician See ‘Astounding Results’ with Drug Combination Targeting COVID-19. [Updated 2021; cited 2021] Available from website: [https://www.trialsitenews.com/bangladesh-medical-college-hospital-physician-see-astounding-results-with-drug-combination-targeting-covid-19/]. Wang S, Liu C, Liu X, He Y, Shen D, Luo Q, Dong Y, Dong H, Pang Z. Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines. Tumour Biol. 2017;39(10):1010428317718192. Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand. [Updated 2021; cited 2021] Available from website: [https://www.the-scientist.com/news-opinion/flu-and-anti-hiv-drugs-show-efficacy-againstcoronavirus-67052]. Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26(1):42. Scheim, David, Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion [Updated 2021; cited 2021] Available from website: [https://ssrn.com/abstract=3636557] Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem Cell Rev Rep. 2020;16(3):434-40. Wang K, Chen W, Zhou YS, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv preprint. 2020:10.1101/2020.03.14.988345. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646-54. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988.